Tuesday, 28 November 2017

Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma

  1. Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma  Markets InsiderFull coverage
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)